498 related articles for article (PubMed ID: 26359256)
1. A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688.
Kostakoglu L; Duan F; Idowu MO; Jolles PR; Bear HD; Muzi M; Cormack J; Muzi JP; Pryma DA; Specht JM; Hovanessian-Larsen L; Miliziano J; Mallett S; Shields AF; Mankoff DA;
J Nucl Med; 2015 Nov; 56(11):1681-9. PubMed ID: 26359256
[TBL] [Abstract][Full Text] [Related]
2. The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
Luo J; Zhou Z; Yang Z; Chen X; Cheng J; Shao Z; Guo X; Tuan J; Fu X; Yu X
Medicine (Baltimore); 2016 Feb; 95(8):e2914. PubMed ID: 26937935
[TBL] [Abstract][Full Text] [Related]
3. Role of
Akimoto E; Kadoya T; Kajitani K; Emi A; Shigematsu H; Ohara M; Masumoto N; Okada M
Clin Breast Cancer; 2018 Feb; 18(1):45-52. PubMed ID: 28993056
[TBL] [Abstract][Full Text] [Related]
4. FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results.
Buchbender C; Kuemmel S; Hoffmann O; Stahl AR; Kimmig R; Otterbach F; Ladd S; Koeninger A; Forsting M; Bockisch A; Antoch G; Heusner TA
Acta Radiol; 2012 Jul; 53(6):628-36. PubMed ID: 22761341
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer.
Woolf DK; Beresford M; Li SP; Dowsett M; Sanghera B; Wong WL; Sonoda L; Detre S; Amin V; Ah-See ML; Miles D; Makris A
Br J Cancer; 2014 Jun; 110(12):2847-54. PubMed ID: 24832174
[TBL] [Abstract][Full Text] [Related]
6. The use of 3'-deoxy-3'-
Ueberroth BE; Lawhorn-Crews JM; Heilbrun LK; Smith DW; Akoury J; Ali-Fehmi R; Eiseler NT; Shields AF
Ann Nucl Med; 2019 Jun; 33(6):383-393. PubMed ID: 30810980
[TBL] [Abstract][Full Text] [Related]
7. The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer.
Lee HW; Lee HM; Choi SE; Yoo H; Ahn SG; Lee MK; Jeong J; Jung WH
J Nucl Med; 2016 Aug; 57(8):1183-8. PubMed ID: 27033896
[TBL] [Abstract][Full Text] [Related]
8. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
[TBL] [Abstract][Full Text] [Related]
9. Early prediction of response to neoadjuvant chemotherapy in breast cancer patients: comparison of single-voxel (1)H-magnetic resonance spectroscopy and (18)F-fluorodeoxyglucose positron emission tomography.
Cho N; Im SA; Kang KW; Park IA; Song IC; Lee KH; Kim TY; Lee H; Chun IK; Yoon HJ; Moon WK
Eur Radiol; 2016 Jul; 26(7):2279-90. PubMed ID: 26376886
[TBL] [Abstract][Full Text] [Related]
10.
Romine PE; Peterson LM; Kurland BF; Byrd DW; Novakova-Jiresova A; Muzi M; Specht JM; Doot RK; Link JM; Krohn KA; Kinahan PE; Mankoff DA; Linden HM
Breast Cancer Res; 2021 Aug; 23(1):88. PubMed ID: 34425871
[TBL] [Abstract][Full Text] [Related]
11. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
Groheux D; Sanna A; Majdoub M; de Cremoux P; Giacchetti S; Teixeira L; Espié M; Merlet P; de Roquancourt A; Visvikis D; Hatt M; Resche-Rigon M; Hindié E
J Nucl Med; 2015 Jun; 56(6):824-31. PubMed ID: 25883123
[TBL] [Abstract][Full Text] [Related]
12. ¹⁸F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study.
Crippa F; Agresti R; Sandri M; Mariani G; Padovano B; Alessi A; Bianchi G; Bombardieri E; Maugeri I; Rampa M; Carcangiu ML; Trecate G; Pascali C; Bogni A; Martelli G; de Braud F
Eur J Nucl Med Mol Imaging; 2015 May; 42(6):818-30. PubMed ID: 25673053
[TBL] [Abstract][Full Text] [Related]
13. In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors.
Vesselle H; Grierson J; Muzi M; Pugsley JM; Schmidt RA; Rabinowitz P; Peterson LM; Vallières E; Wood DE
Clin Cancer Res; 2002 Nov; 8(11):3315-23. PubMed ID: 12429617
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.
Tateishi U; Miyake M; Nagaoka T; Terauchi T; Kubota K; Kinoshita T; Daisaki H; Macapinlac HA
Radiology; 2012 Apr; 263(1):53-63. PubMed ID: 22438441
[TBL] [Abstract][Full Text] [Related]
15.
Chen L; Zheng S; Chen L; Xu S; Wu K; Kong L; Xue J; Chen X; Miao W; Zhu Y
J Nucl Med; 2023 Dec; 64(12):1899-1905. PubMed ID: 37918866
[No Abstract] [Full Text] [Related]
16. Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
Koolen BB; Valdés Olmos RA; Wesseling J; Vogel WV; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Vrancken Peeters MJ
Ann Surg Oncol; 2013 Jul; 20(7):2227-35. PubMed ID: 23456316
[TBL] [Abstract][Full Text] [Related]
17. Textural features of
Cheng L; Zhang J; Wang Y; Xu X; Zhang Y; Zhang Y; Liu G; Cheng J
Ann Nucl Med; 2017 Aug; 31(7):544-552. PubMed ID: 28646331
[TBL] [Abstract][Full Text] [Related]
18. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
19. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.
Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH
J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329
[TBL] [Abstract][Full Text] [Related]
20. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
